The Return of Most Favoured Nation Pricing

The new order is now essentially a return of “Most Favored Nation” (MFN) pricing, which Trump previously and unsuccessfully implemented in his first term. The structure, conceptually, is straightforward: cap U.S. drug prices at the lowest price of any other peer country. International reference pricing is not new, Trump attempted a similar program in 2020 but was stopped through litigation. In that effort, he focused on the most expensive drugs in Medicare and estimated U.S. taxpayer savings of $85 billion over seven years while providing access to lower-cost drugs. It never got off the ground. However, the concept lived on. However, with Trump back in the Oval Office and empowered by an “America First” mandate, MFN pricing is back in style as official policy. The executive order instructs U.S. health agencies to peg what the country pays for drugs to what prices are in other high-income countries — a major deviation from the status quo, more so because U.S. prices are sometimes three times higher than those in other developed countries.

What is, I think, particularly edgy about this resurgence is Trump’s open admission the rest of the world may have to adjust. “They are going to go up all over the World to equal and bring FAIRNESS TO AMERICA!”, he said of drug prices abroad. This means that if America is paying less, drug companies will be able to raise prices elsewhere as an offset. It will certainly receive lots of scrutiny when it is all done, however, there should be no ambiguity about the priority for the Administration: lower bills at U.S. pharmacies, no matter what the downstream consequences may be. The process will likely target Medicare — lobbyists believe the order will apply to more medicines than were included last year in the Inflation Reduction Act for price negotiation for Medicare. However, we just don’t know. Trump made sweeping promises without detailing any process. The hard work — and legal small print — will be left to health officials who have to figure out how to advance “fair” prices without collapsing the system. It is one thing to proclaim that we won’t pay more for insulin than France or Australia, it is another to turn that into actual practice.

Industry vs. Payers: Who Toasts, Who Dreads?

All of this is not without its dissenters. The drug industry fought back strongly, reliving its now familiar tale that any form of government price interference would be harmful to both innovation and patients. “Government price setting in any form is bad for American patients,” Alex Schriver, spokesman for PhRMA — the powerful lobby for drug makers. One executive said that Trump’s pricing proposal is “the largest, multifaceted existential threat to the industry and U.S. biosciences innovation.” In other words, for Big Pharma, this is not just an adjustment but a threat to their business model of high U.S. margins funding drug research. Wall Street took note. As more of Trump’s plan became clearer, shares of pharma began to tumble globally, with the U.S. pharma heavyweights Pfizer and Merck down approximately 2–4% and European drug makers with shares down over 3% apiece. In Japan, pharmaceutical shares were knocked down over 6%. The market is treating this as a real risk to future profits and potentially the large R&D budgets that depend on those profits.

On the other side of the ledger, payers and insurers are quietly smiling. For them, Trump’s order is essentially a gilt-edged cost cut. If both Medicare and private plans can pay European-level prices for cutting-edge therapies, the savings would be enormous, if the multiple middlemen allow it. Keep in mind that the U.S. spends over $400 billion a year on drugs, it is a tiny proportion of health spending, but still 30% off is a lot of spending power freed up.) For government health programmes, such as Medicare, the potential upside is almost experimental; as earlier mentioned, the MFN demo would have nearly cut Medicare pharmaceutical spending in half! It is hardly surprising that public support for reducing drug prices is a strong position that crosses party lines. Payers see an opportunity to potentially save some money, and patient advocates hope this may yield lower premiums or out-of-pocket costs — the question is, will it? That is less than clear. In theory, insurers could work to give that money back to their customers by also having lower premiums or by expanding coverage. But in practice, the real question is: what percentage of that windfall will be rebated to consumers after claim settlements at the pharmacy counter? The U.S. healthcare system is not exactly known for its rapid generosity. Any premium reductions will likely come slowly and through competitive pressure or regulation. Nevertheless, there is cautious optimism. At a minimum, it is believed that Medicare beneficiaries will see at least some reduction in their Part D premiums or out-of-pocket cost sharing if the government’s costs from expensive drugs come crashing downward.

Global Impact: Who Else Pays?

While President Trump’s executive order may proclaim “America First,” the shocks to the rubble of the global drug market are now outlined. Drug manufacturers do not simply sit tightly with lower revenues — they attempt to “equalise” lower prices by seeking additional money. So what happens if the U.S. says it will only pay what we pay for cancer drugs in the UK or Poland? For the manufacturer, what’s the easiest solution? Raise prices in the UK? Not likely; this would need a further Health Technology Assessment (HTA), which significantly influences drug prices, primarily through the National Institute for Health and Care Excellence (NICE) in England and the Scottish Medicines Consortium (SMC) in Scotland.

In particular, global health advocates are uneasy. Do we create upward price pressure in Europe or other high-income markets as companies seek to recover their U.S. losses? The early signs are indeed for upward price pressure. “This announcement is likely to have an impact on EU–US tariff negotiations… Is the U.S. president about to impose price caps on pharmaceutical imports rather than tariffs?” “If yes, this may have significant implications” for pharma companies and profits in Europe and perhaps elsewhere,” said one market analyst, pointing to possible trade friction if Europe is unwilling to change as well. In reality, European governments might very well push back against major price increases — they will not simply throw open the purse if U.S. policy changes. But pharma negotiators will “definitely” try to squeeze higher reimbursements from any country that has benefitted from significant discounting so far. The power dynamic in price negotiations could change: companies may tell EU health ministries, implicitly, “Pay up, or the consequences of America’s low price deal means we will no longer sell to you at a discount again.” Some even predict drug makers will delay the launches of new medicines, specifically in lower-price countries, to ensure that there is no “cheap” reference pricing that undermines their U.S. price.

This is not unprecedented. In Europe, international reference pricing has already been shown to influence delays in European access to new drugs in lower-income EU members. One study noted that international reference pricing caused about half of all delays in new drug launches in lower-income European countries (about one-year delays on average). In practice, a company might delay the launch of a breakthrough therapy in, say, Poland or Greece, until a higher price has been negotiated in Germany and France so these lower-price markets don’t pull down the global average. Trump’s global price peg could exaggerate these dynamics. If a U.S. reimbursement can be larger by any country offering a lower price, pharma companies will be even more resistant to lower prices. Low-income countries or lower-margin markets could be the hardest hit. They might have inflated prices, or they might simply be deprioritised — fewer affordable options, longer waits for new drugs, or products leaving those markets altogether. As one analysis suggested, manufacturers would be motivated to “reduce or even terminate the discounts they offer other countries”, putting pressure on those countries to pay significantly higher prices. Indeed, Trump’s own policy team has, essentially, recognised this trade-off: their expectation is other countries will, in our case, contribute more, i.e. pay closer to what Americans are paying. Great for the U.S. health dollar; not so great if you are a patient or an insurer in a country that, until now, benefitted from lower costs negotiated on a good-faith basis.

And what of patients in poorer countries? While Trump’s MFN model will likely primarily focus on high-income counterparts (no one would expect the U.S. drug price to be pegged to the lowest price for its product in sub-Saharan Africa, for example), there could still be spillover effects that might affect middle-income countries. Global health organisations fear if pharmaceutical companies cannot segment the market (i.e. more for rich countries and less for poor ones), they will stop doing business entirely in lower-profit markets. The unintended result of a goodwill reform of U.S. costs could be reduced access to innovative medicines in places that could least afford that reduction. As experts have cautioned, linking U.S. prices to other countries can result in “unintended complications, such as delaying drug entry in other countries and raising prices abroad.” Put bluntly, Americans may pay less, but some of that cost may just be shifted onto sick people elsewhere.

Where next on the outlook?

Will this policy be delivered to U.S. citizens? It is certainly possible, especially in the short run. If implemented quickly and thoroughly, Americans might see significant drops in many brand-name drugs — particularly, high-cost treatments for things like cancer, rheumatoid arthritis, and multiple other conditions where U.S. prices are considerably higher than in much of the world. But there is no free lunch. Someone pays the costs for drug research and manufacturing, and Trump is betting the rest of the wealthy world will pick up more of the costs so that Americans will have to pay less. Drug companies, not too surprisingly, will be all-out protecting their R&D budgets and profits — whether they do that by litigating (as they did the last time), negotiating harder against the health systems in Europe and Asia, or cutting costs somewhere else in their operations (like R&D, when their revenue estimates go south). The push-pull between the pharmaceutical industry and government will be furious.

For payers (like insurers and government programmes), this is clearly a nice win for them — it could potentially reduce the amount of money they spend. But whether or not American patients are able to see that in their pockets will depend on the details of implementation and ongoing enforcement at all levels. Reduced drug prices may translate into reduced insurance premiums and reduced taxpayer funding (in theory), provided the healthcare system appropriately passes along those savings. There is every chance that the opposite will occur. After all, the U.S. supply chain for drugs is complicated, with all of the middlemen, pharmacy benefit managers, and insurance entities taking their cuts. There would need to be heavy observation to ensure that price reductions at the highest level do not become additional profits for the next tier of entities in the long supply chain.

We will be watching carefully

Trump’s pharmaceutical international pricing order is a high-stakes experiment to reform drug pricing and challenge the pharmaceutical sector’s price-setting practices. It is also a step toward reclaiming some balance back to U.S. payers. It is also possible that, if implemented appropriately, it could mean that American patients have greater access to cutting-edge medicines at affordable prices if it can bring down what Americans pay for the same pills cheaper abroad. That is a relief many have been waiting for. It also exports the issue.

The neutral, critical reality is this: Someone pays for innovation. As is always the case with Trump, he talks a big game, but the end result remains to be seen. For now, Americans have been promised lower drug bills. The world will be waiting for the bill.

FINN Partners will be watching this develop and continue to analyse the situation.

The post Trump’s Drug Price Gambit: Cheaper for America, But Who Pays the Price? appeared first on Medika Life.

This move benefits Indian patients and has the potential to reshape the global pharmaceutical landscape. With India’s new policy, many multinational biopharmaceutical companies will need to reflect on how India evolves into a priority market.  

Speaking on the decision, Dr. V.G. Somani, Drugs Controller General of India (DCGI), Central Drugs Standard Control Organization, stated, “This policy shift is designed to bring the best of global medical innovation to India more swiftly. By relying on the robust data from international trials, we can ensure that Indian patients benefit from these advancements without unnecessary delays.”

This is more than just a regulatory update for multinational biopharmaceutical companies—it’s a strategic inflection point. India has long been considered a market of interest due to its significant population, favorable policy environment, and emerging middle class. Now, it has signaled its readiness to engage with the global pharmaceutical ecosystem on a new level.

The shift opens up a new market for these pharma companies. It presents an opportunity, but more importantly, a responsibility to extend their voice in India, increasing corporate brand reputation, science communication, and patient advocacy. It’s a turning point that could redefine the global pharmaceutical landscape, underscoring the weight of their role in shaping the future of healthcare.

S. Rajan, Chief Communications, Corporate Affairs and CSR officer at Roche, is among the industry leaders who applauded the GoI news: “This circular is a welcome and much-needed move. The calling out of specific drug categories will help drive a uniform and consistent understanding and avoid any delays. It is important that this is implemented well. We are hopeful that access to the latest innovations will be expedited, addressing unmet healthcare needs and benefitting Indian patients.”

Eliminating the cost barrier of conducting local clinical trials indicates that the GoI is seeking to address a public health need.  One obstacle has been removed, though others remain. Global biopharma companies still face significant challenges operating in India, primarily due to price controls impacting innovative therapies. At this time, India’s government enforces price caps that too often make it financially unviable for multinational companies to launch new, innovative drugs in this market. But it’s not impossible!

This is a favorable move to bring innovative cancer therapies and treatments for rare diseases to people in India. This remains a market of incredible potential, and biopharma companies will need to continue advancing innovative therapies and supporting them with economic solutions to make the best medicines available to more people worldwide. In the meantime, an expansion strategy to India is a medical and communication priority.

Investing in Corporate Brand Reputation

With India becoming a priority market, global pharmaceutical companies must assess how to build relationships with India’s medical and patient advocacy communities.  This is more than relying on marketing muscle. It’s about establishing a reputation as a trusted partner in health innovation and delivery in fast-emerging nations. This could involve initiatives such as collaborating with local healthcare providers, supporting patient education programs, and participating in policy discussions on health innovation and delivery in India.

Even before the GoI decision, the Indian pharmaceutical market was expected to grow to US$130 billion by 2030, up from US$42 billion in 2021, making it one of the fastest-growing health markets in the world.  The decision to embrace other nations’ regulatory moves will likely dramatically accelerate that growth.

Patrizia Cavazzoni, MD, Center for Drug Evaluation and Research, at FDA, has long tracked GoI decisions: “India’s decision to align its drug approval processes with global standards is a significant step that will foster greater collaboration. It also highlights the need for pharmaceutical companies to engage more deeply with Indian stakeholders, ensuring their corporate presence is synonymous with trust and transparency.”

Like audiences everywhere, the Indian public is increasingly discerning the corporate behaviors of those they entrust with their health.  People with urgent health concerns are excited about this decision, which will speed up access to therapies.  Companies must recognize that investing in world-class science may not be enough in the post-COVID era to secure physician support and consumer confidence.  To facilitate market entry in India requires establishing corporate identities people can trust.

The Imperative for Science-Based Communication

Effective science communication will be paramount as these companies introduce their health innovations into India. The complexities of advanced medical treatments, particularly newly approved ones, require careful explanation to health providers and the public.

Transparent, accessible communication will help demystify these innovations, fostering greater acceptance and understanding.  This also calls on major hospital provider systems that served as drug trial sites for these regulatory-approved medicines to step forward and share clinical backgrounds and best practices in patient care.

According to published studies, 87% of Indian physicians are highly engaged in continuing medical education (CMEs) and are keen to stay updated with the latest advancements in treatments and drug safety protocols, highlighting a receptive audience for apparent, data-driven communication efforts. Companies have an opportunity to lead by example, demonstrating that they are bringing innovative products to market by showing commitment to educating and empowering Indian patients and health professionals.

Dr. V.G. Somani, DCGI, emphasized the importance of clear communication in this new regulatory landscape: “Pharmaceutical companies must now rise to the challenge of effectively communicating the science behind these treatments to healthcare providers and patients. This will be crucial in ensuring that the benefits of these new therapies are fully realized.”

Patient Advocacy as a Pillar of Reputation

Most crucially, multinational pharmaceutical companies must prioritize patient advocacy in India. The recent regulatory change will undoubtedly bring some innovative treatments to the market. The policy change is a catalyst toward ensuring treatments are accessible, affordable, and aligned with patients’ needs.  However, it remains a complex challenge.  India has 1.4 billion people – as many as 400 million classified as middle class – and a diverse and complex healthcare insurance system that includes government, private, and, in some cases, a heavy reliance on consumer out-of-pocket payments.

Companies must engage with patient communities, understand their unique challenges, and advocate for solutions that address them. Organizations such as the Organization for Rare Diseases India (ORDI) and the Lysosomal Storage Disorders Support Society (LSDSS) are among the advocacy groups advocating for patients with rare diseases in India. ORDI ensures early diagnosis, treatment, and support for individuals with rare diseases, while LSDSS focuses on increasing awareness and providing access to therapies for lysosomal storage disorders.

Dr. Manjit Singh, LSDSS Executive Committee President, commented on the significance of this regulatory change: “This policy decision is a critical step forward for patients with rare diseases in India. It will help bring much-needed therapies to the market faster. Still, it also places the onus on pharmaceutical companies to ensure these treatments are accessible and affordable for all patients.”

By engaging with these patient advocacy groups, pharmaceutical companies can help amplify patients’ voices, ensuring their needs are central in developing and distributing new treatments. Over time, this will include ensuring peer-reviewed science is shared with India-based media covering health and science, prioritizing pricing strategies to ensure accessibility to patient support programs, and investing in awareness efforts so that people with these conditions understand the importance of medication adherence.

The Government of India’s decision to waive local clinical trial requirements for drugs approved by gold-standard regulatory bodies is forward-thinking and aligns with the country’s demonstrated efforts to improve health delivery for serious illnesses. Multinational biopharmaceutical companies should get the signal that India is a welcoming market ready to be at the forefront of their phyician education and patient advocacy efforts. By investing in corporate brand awareness, scientific communication, and patient advocacy, these companies can contribute meaningfully to the health and well-being of India and other emerging nations. 

One barrier to access has been lowered for innovative cancer and rare disease therapies.  In reality, others remain.  One of the biggest is that the Indian National Pharmaceutical Pricing Authority sets ceiling prices – caps – that include certain patented and innovative drugs. The pricing formula often uses a cost-plus approach, a non-starter for significant biopharma companies championing breakthrough therapies in a price-referring policy environment.  But the door to possibilities has opened wider.

In responding to the GoI welcoming decision with action, the biopharmaceutical industry can reinforce its commitment to good business, science, and patient care—a true win-win-win for all involved and a global health impact. The message is clear: Pharma companies consider the possibilities and  “Go to India!”

The post India’s Pivotal Regulatory Shift: A Possible Game-Changer in Expediting Medicines to Millions in Dire Need appeared first on Medika Life.